藥物輸送的全球市場:藥物用量，藥價，銷售額，臨床試驗趨勢(2030年)

藥物輸送的全球市場:藥物用量，藥價，銷售額，臨床試驗趨勢(2030年)報告觀察和亮點:

• 研究方法
• 全球及區域市場概覽
• 全球市場規模（十億美元）：2022-2030 年
• 全球市場機會：超過 900 億美元
• 臨床試驗中控釋藥物的洞見：超過 190 種產品
• 按公司、適應症和階段劃分的全球控釋藥物臨床管線
• 已獲批准和上市的控釋藥物的洞察：超過 180 種產品
• 控釋藥物的劑量、定價與銷售洞察
• 競爭激烈前景

控釋系統需求及本報告意義

隨著醫護人員和病患尋求更優質、更便捷、更安全的治療方案，對控釋系統的需求日益增長。糖尿病、心血管疾病和神經系統疾病等慢性疾病需要長期治療，而傳統給藥方式的限制（例如重複給藥和藥物吸收不穩定）往往會降低療效。控釋系統透過長時間維持穩定的藥物濃度、最大限度地減少給藥頻率和提高療效來解決這些問題。控釋系統還有助於減少副作用、提高患者依從性並優化藥物藥物動力學。

本報告深入探討了控釋給藥技術不斷發展的前景，重點介紹了創新技術、臨床趨勢和關鍵市場參與者。隨著對改進藥物輸送的需求不斷增長，本分析將為這個不斷增長的市場提供未來成長和機會的洞察。除了最新的技術發展和新興趨勢外，該報告還包含 60 多種藥物的詳細定價數據以及特定產品的銷售業績數據。這些策略建議和市場數據的結合，有助於市場參與者在藥物開發、交付和商業化方面做出明智的決策。

報告中包含的臨床試驗洞察

臨床試驗對於驗證控釋藥物傳遞系統的有效性和安全性至關重要。本報告對幾項關鍵臨床試驗進行了深入分析，並展望了該領域的發展。本部分提供的資訊包括試驗階段、申辦者、地理分佈、技術提供者、合作者和許可證持有者。試驗涵蓋了從疼痛管理和腫瘤學到神經系統和代謝疾病等各種治療類別。

活躍於控釋藥物輸送系統研發的主要公司

目前，許多大型製藥和生技公司都在致力於控釋藥物輸送系統的開發。這些公司是研發領域的領導者，採用先進技術開發更有效率、更方便患者的藥物。本報告列舉了艾伯維、阿斯特捷利康和默克等知名公司，它們正在探索新的藥物傳遞平台，以增強慢性病、癌症、神經系統疾病和代謝性疾病的治療效果。

除了大型製藥公司外，一些規模較小的新創公司也在開發新型控釋系統方面處於領先地位。 SpyGlass Pharma 和 Glaukos Corporation 等公司正在課題眼科領域控釋平台的局限性，而勃林格殷格翰和 Re-Vana Therapeutics 等合作夥伴正在開發用於治療視網膜疾病的可生物降解植入物。我們也討論了這些合作如何推動新一代藥物遞送系統的商業化。

報告展示了控釋藥物遞送系統領域的未來發展方向

預期控釋藥物遞送系統未來將迎來顯著的成長和發展。報告指出，生物技術和數位醫療的進步將推動更個人化、更有針對性的藥物傳遞機制的應用。精準醫療的興起將推動客製化藥物輸送系統的研發，以滿足每位患者的需求，從而進一步提高治療效果和患者依從性。

此外，我們的研究預測，包括植入式系統和透皮貼片在內的非侵入性藥物傳遞技術因其便利性和患者不適感最小而將得到更廣泛的應用。神經退化性疾病、個人化腫瘤治療和罕見疾病領域應用的不斷擴展也有望推動市場向前發展。

持續的研發投入和對創新藥物輸送技術的監管支持力度的加大，將維持受控藥物輸送系統市場的成長，為開發這些先進療法的公司提供重大機會。

目錄

第1章 控制型藥物輸送的簡介

• 基礎與技術
• 系統，途徑，各技術分類
• 作用機制

第2章 控制型藥物輸送的基於材料方法

• 聚合物
• 時間藥劑學
• 奈米粒子通知系統

第3章 全球緩釋性藥物輸送市場趨勢

• 目前市場情勢
• 未來市場預測

第4章 控製藥物輸送的研究和臨床趨勢，各適應症

• 神經疾病
• 心血管疾病
• 糖尿病
• 癌症
• 微生物感染疾病

第5章 全球緩釋性醫藥品市場趨勢，各地區

• 美國
• 歐洲
• 日本
• 中國
• 加拿大
• 韓國

第6章 各企業，各適應症，各期的世界緩釋性醫藥品的臨床實驗平台

• 研究
• 前臨床
• 第一階段
• 第一/二階段
• 第二階段
• 第二/三階段
• 第三階段
• 預註冊
• 登記完畢

第7章 上市的緩釋性醫藥品的各企業，各國，各適應症的臨床性洞察

第8章 阿茲海默症的緩釋性藥物- 價格和用量的考察

• Namzaric(緩釋性)
• NamendaXR(緩釋性)
• Razadyne ER(緩釋性)

第9章 帕金森氏症的緩釋性藥物- 價格和用量的考察

• Gocovri (緩釋性)
• Osmolex ER (緩釋性)
• Mirapex ER (緩釋性)

第10章 思覺失調症的緩釋性藥物- 價格和用量的考察

• Invega (緩釋性)
• Invega Franchise/Invega Hafyera (緩釋性)
• Seroquel XR (緩釋性)
• Abilify Franchise (緩釋性)
• Aristada/Aristada Initio (緩釋性)
• Rykindo (緩釋性)
• Risperdal Consta (緩釋性)
• Uzedy (緩釋性)

第11章 對慢性疼痛及手術後疼痛的緩釋性藥物- 價格和用量的考察

• 11.1 Hysingla ER (緩釋性)
• 11.2 Nucynta ER (緩釋性)
• 11.3 Kadian (緩釋性)
• 11.4 Xtampza ER (緩釋性)
• 11.5 MS Contin (緩釋性)
• 11.6 Embeda (緩釋性)
• 11.7 Posimir (Sustained-Release)
• 11.8 Zynrelef (緩釋性)
• 11.9 ConZip (緩釋性)
• 11.10 Generic Hydromorphone (緩釋性)

第12章 對多發性硬化症的緩釋性藥物- 價格和用量的考察

• Ampyra/Fampyra (緩釋性)
• Tecfidera (Delayed-Release)
• Vumerity (Delayed-Release)
• Rayos (Delayed-Release)
• Bafiertam (Delayed-Release)

第13章 對第二型糖尿病的緩釋性藥物- 價格和用量的考察

• Glumetza (緩釋性)
• Glucotrol XL (緩釋性)
• Glucophage XR (緩釋性)
• Trijardy XR (緩釋性)
• Synjardy XR (緩釋性)

第14章 對心血管疾病的緩釋性藥物- 價格和用量的考察

• Procardia XL (緩釋性)
• Toprol XL (緩釋性)
• Verelan PM (緩釋性)
• Cardizem LA (緩釋性)
• Calan SR (Sustained-Release)
• Altoprev (緩釋性)
• Cardura XL (緩釋性)

第15章 對HIV的緩釋性藥物- 價格和用量的考察

• Apretude (緩釋性)
• Cabenuva (緩釋性)
• Rukobia (緩釋性)

第16章 對注意缺陷·多動性障礙(ADHD)的緩釋性藥物- 價格和用量的考察

• Qelbree (緩釋性)
• Jornay PM (緩釋性)
• Cotempla XR-ODT (緩釋性)
• Adzenys XR-ODT (緩釋性)
• Intuniv (緩釋性)
• Focalin XR (緩釋性)

第17章 對發炎性疾病及自體免疫疾病的緩釋性藥物- 價格和用量的考察

• Rinvoq (緩釋性)
• Ortikos (緩釋性)
• Xeljanz XR (緩釋性)
• Mestinon Timespan (緩釋性)
• Symax Duotab (緩釋性)

第18章 對細菌感染疾病的緩釋性藥物- 價格和用量的考察

• Aemcolo (Delayed-Release)
• Talicia (Delayed-Release)

第19章 對類鴉片物質使用障礙的緩釋性藥物- 價格和用量的考察

• Sublocade (Sustained-Release)
• Brixadi (緩釋性)

第20章 器官移植排斥反應抑制的緩釋性藥物- 價格和用量的考察

• Astagraf XL (緩釋性)
• Envarsus XR (緩釋性)

第21章 與偏頭痛對發作的緩釋性藥物- 價格和用量的考察

• Trokendi XR (緩釋性)
• Oxtellar XR (緩釋性)
• Keppra XR (緩釋性)
• Roweepra XR (緩釋性)
• Depakote, Depakote ER, & Depakote Sprinkles

第22章 對精神疾病及睡眠障礙的緩釋性藥物- 價格和用量的考察

• Effexor XR (緩釋性)
• Xanax XR (緩釋性)
• Ambien CR (緩釋性)

第23章 對代謝·電解質異常的緩釋性藥物- 價格和用量的考察

• Klor-Con 8, Klor-Con 10, Klor-Con M10, Klor-Con M15, Klor-Con M20

第24章 世界的藥物遞輸系統市場動態

• 推動市場要素和機會
• 市場課題與阻礙因素

第25章 競爭情形

• AbbVie
• Antlia Bioscience
• Arbor Pharmaceuticals (Azurity Pharmaceuticals)
• AstraZeneca
• Bausch Health Companies
• Biodexa Pharmaceuticals
• Boehringer Ingelheim
• Camurus
• DURECT Corporation
• Emplicure
• HLK Pharmacin
• Jemincare
• Johnson & Johnson
• Luye Pharma Group
• Lyndra
• Mallinckrodt plc
• MedinCell S.A.
• Merck
• Otsuka Pharmaceutical
• Pacira BioSciences
• Pfizer
• Purdue Pharma
• Roche
• Sanofi
• Serina Therapeutics
• Sun Pharmaceutical Industries
• Supernus Pharmaceuticals
• Takeda
• Tris Pharma
• ViiV Healthcare

Global Controlled Release Drug Delivery Market, Drug Dosage, Price, Sales & Clinical Trials Insight 2030 Report Finding & Highlights:

• Research Methodology
• Global & Regional Market Overview
• Global Market Size Insight In US$ Billion: 2022 - 2030
• Global Market Opportunity: > US$ 90 Billion
• Insight On Controlled Release Drugs In Clinical Trials: > 190 Drugs
• Global Controlled Release Drugs Clinical Pipeline By Company, Indication & Phase
• Insight On Approved & Marketed Controlled Release Drugs: > 180 Drugs
• Controlled Release Drugs Dosage, Pricing & Sales Insight
• Competitive Landscape

Need for Controlled Drug Release Systems & Why This Report?

The demand for controlled drug release systems has increased as both healthcare practitioners and patients seek improved, more convenient, and safer therapeutic regimens. Chronic diseases like diabetes, cardiovascular diseases, and neurological disorders call for long-term therapy, and the limitations associated with conventional dosing, such as repeated administration and variable drug absorption, frequently undermine treatment efficacy. Controlled drug release systems resolve these issues by maintaining uniform levels of drugs for a prolonged duration, minimizing the frequency of dosing, and improving the therapeutic efficacy. Controlled drug release systems also assist in the reduction of side effects, patient compliance, and the optimization of the pharmacokinetics of drugs.

This report gives an in-depth look at the changing landscape of drug controlled release technologies, underlining the innovations, clinical trends, and key market players. With the demand for improved drug delivery increasing, this analysis is an eye opener to future growth and opportunities in this growing market. Apart from the latest technological developments and emerging trends, it also contains in-depth pricing data for more than 60 medicines, as well as sales performance data for specific products. This blend of strategic recommendations and market data is meant to guide industry participants, enabling them to make informed decisions in drug development, delivery, and commercialization.

Clinical Trials Insight Included In Report

Clinical trials are crucial in validating the efficacy and safety of drug delivery systems with controlled release. There are detailed insights into several key clinical trials in this report, and giving a preview of the development in the area. The information provided in this section specifically comprises stages of trials, sponsors, geographical distribution, technology providers, collaborators and license holders. The trials cover a variety of therapeutic categories, including pain management and oncology to neurological diseases and metabolic disorders.

Major Companies Active In R&D of Controlled Drug Release Systems

A number of major pharmaceutical and biotech firms are currently engaged in the development of controlled drug release systems. These firms are leaders in R&D activities, employing advanced technologies to develop more efficient and patient-friendly medicines. The report identifies prominent players like AbbVie, AstraZeneca, and Merck, which are looking for novel drug delivery platforms to enhance the treatment of chronic diseases as well as conditions like cancer, neurological disorders, and metabolic disorders.

Along with major pharmaceutical firms, smaller startups are also taking lead in creating new controlled release systems. Firms such as SpyGlass Pharma and Glaukos Corporation are pushing the boundaries of controlled-release platforms in ophthalmology, whereas partnerships like that of Boehringer Ingelheim with Re-Vana Therapeutics are developing biodegradable implants for retinal illnesses. The report also explains how these collaborations are spurring the commercialization of new-generation drug delivery systems.

Report Indicating Future Direction Of Controlled Drug Release Systems Segment

The future for controlled drug release systems promises significant growth and development. According to the report, the emphasis will be placed on the use of more personalized and targeted drug delivery mechanisms, sparked by developments in biotechnology and digital health technologies. The advent of precision medicine will propel the creation of customized drug release systems that respond to each patient's requirements, even further enhancing the effectiveness of treatment and patients' compliance.

Moreover, our research anticipates a wider use of non-invasive drug delivery techniques, including implantable systems and transdermal patches, as they are convenient and cause less discomfort to patients. Increasing applications in neurodegenerative disorders, personalized oncology, and rare diseases will also propel the market forward.

As investment in R&D continues and regulatory backing for innovative drug delivery technologies is further enhanced, controlled drug release system market growth will persist, presenting substantial opportunities for firms developing such sophisticated therapies.

Table of Contents

1. Introduction To Controlled Drug Delivery

• 1.1 Fundamentals & Technology
• 1.2 Classification By System, Route & Technology
• 1.3 Mechanisms Of Action

2. Material Based Approaches For Controlled Drug Delivery

• 2.1 Polymers
• 2.2 Chronopharmaceutics
• 2.3 Nanoparticulate Delivery System

3. Global Controlled Release Drug Delivery Market Trends

• 3.1 Current Market Scenario
• 3.2 Future Market Outlook

4. Controlled Drug Delivery Research & Clinical Trends By Indication

• 4.1 Neurological Disorders
• 4.2 Cardiovascular Diseases
• 4.3 Diabetes
• 4.4 Cancer
• 4.5 Microbial Infections

5. Global Controlled Release Drug Market Trends By Region

• 5.1 US
• 5.2 Europe
• 5.3 Japan
• 5.4 China
• 5.5 Canada
• 5.6 South Korea

6. Global Controlled Release Drugs Clinical Pipeline By Company, Indication & Phase

• 6.1 Research
• 6.2 Preclinical
• 6.3 Phase-I
• 6.4 Phase-I/II
• 6.5 Phase-II
• 6.6 Phase-II/III
• 6.7 Phase-III
• 6.8 Preregistration
• 6.9 Registered

7. Marketed Controlled Release Drugs Clinical Insight By Company, Country & Indication

8. Controlled Release Drugs for Alzheimer's Disease - Pricing & Dosage Insight

• 8.1 Namzaric (Extended-Release)
• 8.2 Namenda XR (Extended-Release)
• 8.3 Razadyne ER (Extended Release)

9. Controlled Release Drugs for Parkinson's Disease - Pricing & Dosage Insight

• 9.1 Gocovri (Extended-Release)
• 9.2 Osmolex ER (Extended-Release)
• 9.3 Mirapex ER (Extended-Release)

10. Controlled Release Drugs for Schizophrenia - Pricing & Dosage Insight

• 10.1 Invega (Extended-Release)
• 10.2 Invega Franchise/Invega Hafyera (Extended-Release)
• 10.3 Seroquel XR (Extended-Release)
• 10.4 Abilify Franchise (Extended-Release)
• 10.5 Aristada/Aristada Initio (Extended-Release)
• 10.6 Rykindo (Extended-Release)
• 10.7 Risperdal Consta (Extended-Release)
• 10.8 Uzedy (Extended-Release)

11. Controlled Release Drugs for Chronic & Post-Operative Pain - Pricing & Dosage Insight

• 11.1 Hysingla ER (Extended-Release)
• 11.2 Nucynta ER (Extended-Release)
• 11.3 Kadian (Extended-Release)
• 11.4 Xtampza ER (Extended-Release)
• 11.5 MS Contin (Extended-Release)
• 11.6 Embeda (Extended-Release)
• 11.7 Posimir (Sustained-Release)
• 11.8 Zynrelef (Extended-Release)
• 11.9 ConZip (Extended-Release)
• 11.10 Generic Hydromorphone (Extended-Release)

12. Controlled Release Drugs for Multiple Sclerosis - Pricing & Dosage Insight

• 12.1 Ampyra / Fampyra (Extended-Release)
• 12.2 Tecfidera (Delayed-Release)
• 12.3 Vumerity (Delayed-Release)
• 12.4 Rayos (Delayed-Release)
• 12.5 Bafiertam (Delayed-Release)

13. Controlled Release Drugs for Diabetes Mellitus Type II - Pricing & Dosage Insight

• 13.1 Glumetza (Extended-Release)
• 13.2 Glucotrol XL (Extended-Release)
• 13.3 Glucophage XR (Extended-Release)
• 13.4 Trijardy XR (Extended-Release)
• 13.5 Synjardy XR (Extended-Release)

14. Controlled Release Drugs for Cardiovascular Diseases - Pricing & Dosage Insight

• 14.1 Procardia XL (Extended-Release)
• 14.2 Toprol XL (Extended-Release)
• 14.3 Verelan PM (Extended-Release)
• 14.4 Cardizem LA (Extended-Release)
• 14.5 Calan SR (Sustained-Release)
• 14.6 Altoprev (Extended-Release)
• 14.7 Cardura XL (Extended-Release)

15. Controlled Release Drugs for HIV - Pricing & Dosage Insight

• 15.1 Apretude (Extended-Release)
• 15.2 Cabenuva (Extended-Release)
• 15.3 Rukobia (Extended-Release)

16. Controlled Release Drugs for Attention Deficit Hyperactivity Disorder - Pricing & Dosage Insight

• 16.1 Qelbree (extended-release)
• 16.2 Jornay PM (Extended-Release)
• 16.3 Cotempla XR-ODT (Extended-Release)
• 16.4 Adzenys XR-ODT (Extended-Release)
• 16.5 Intuniv (Extended-Release)
• 16.6 Focalin XR (Extended-Release)

17. Controlled Release Drugs for Inflammatory & Autoimmune Diseases - Pricing & Dosage Insight

• 17.1 Rinvoq (Extended-Release)
• 17.2 Ortikos (Extended-Release)
• 17.3 Xeljanz XR (Extended-Release)
• 17.4 Mestinon Timespan (Extended-Release)
• 17.5 Symax Duotab (Extended-Release)

18. Controlled Release Drugs for Bacterial Infections - Pricing & Dosage Insight

• 18.1 Aemcolo (Delayed-Release)
• 18.2 Talicia (Delayed-Release)

19. Controlled Release Drugs for Opioid Use Disorder - Pricing & Dosage Insight

• 19.1 Sublocade (Sustained-Release)
• 19.2 Brixadi (Extended-Release)

20. Controlled Release Drugs for Preventing Organ Transplant Rejection - Pricing & Dosage Insight

• 20.1 Astagraf XL (Extended-Release)
• 20.2 Envarsus XR (Extended-Release)

21. Controlled Release Drugs for Migraine & Seizure - Pricing & Dosage Insight

• 21.1 Trokendi XR (Extended-Release)
• 21.2 Oxtellar XR (Extended-Release)
• 21.3 Keppra XR (Extended-Release)
• 21.4 Roweepra XR (Extended-Release)
• 21.5 Depakote, Depakote ER, & Depakote Sprinkles

22. Controlled Release Drugs for Mental Health and Sleep Disorders - Pricing & Dosage Insight

• 22.1 Effexor XR (Extended-Release)
• 22.2 Xanax XR (Extended-Release)
• 22.3 Ambien CR (Extended-Release)

23. Controlled Release Drugs for Metabolic and Electrolyte Disorders - Pricing & Dosage Insight

• 23.1 Klor-Con 8, Klor-Con 10, Klor-Con M10, Klor-Con M15, Klor-Con M20

24. Global Controlled Drug Delivery System Market Dynamics

• 24.1 Market Drivers & Opportunities
• 24.2 Market Challenges & Restraints

25. Competitive Landscape

• 25.1 AbbVie
• 25.2 Antlia Bioscience
• 25.3 Arbor Pharmaceuticals (Azurity Pharmaceuticals)
• 25.4 AstraZeneca
• 25.5 Bausch Health Companies
• 25.6 Biodexa Pharmaceuticals
• 25.7 Boehringer Ingelheim
• 25.8 Camurus
• 25.9 DURECT Corporation
• 25.10 Emplicure
• 25.11 HLK Pharmacin
• 25.12 Jemincare
• 25.13 Johnson & Johnson
• 25.14 Luye Pharma Group
• 25.15 Lyndra
• 25.16 Mallinckrodt plc
• 25.17 MedinCell S.A.
• 25.18 Merck
• 25.19 Otsuka Pharmaceutical
• 25.20 Pacira BioSciences
• 25.21 Pfizer
• 25.22 Purdue Pharma
• 25.23 Roche
• 25.24 Sanofi
• 25.25 Serina Therapeutics
• 25.26 Sun Pharmaceutical Industries
• 25.27 Supernus Pharmaceuticals
• 25.28 Takeda
• 25.29 Tris Pharma
• 25.30 ViiV Healthcare

List of Figures

• Figure 1-1: Conventional Drug Delivery Systems - Limitations
• Figure 1-2: Novel Drug Delivery Platform Diversification
• Figure 1-3: Evolution Of Drug Delivery Technology: 1st to 3rd Generation
• Figure 1-4: Challenges Addressed By Third Generation Drug Delivery
• Figure 1-5: Targeted vs. Non-Targeted Drug Delivery
• Figure 1-6: Zero-Order Controlled Drug Release
• Figure 1-7: Plasma Concentration-Time Profile: Conventional vs. Controlled Release
• Figure 1-8: Comparison Of Modified Drug Release Systems
• Figure 1-9: Pulsatile Drug Release Mechanism In Pulsincap
• Figure 1-10: Classification By Technical Complexity
• Figure 1-11: Structural Differences Among Drug Delivery Systems
• Figure 1-12: Classification By Route of Administration
• Figure 1-13: Types Of Diffusion-Controlled Mechanisms
• Figure 1-14: Encapsulation Dissolution-Controlled Mechanism
• Figure 1-15: Osmotic Controlled Drug Release
• Figure 1-16: Erosion Mechanisms In Matrix Systems
• Figure 2-1: Polymeric Controlled Drug Delivery Devices - Categories
• Figure 2-2: Nanostructures For Nanoparticulate Delivery Systems
• Figure 3-1: Global - Controlled Release Drug Delivery Market Size (US$ Billion), 2022 - 2025
• Figure 3-2: Global - Controlled Release Drug Delivery Market Forecast (US$ Billion), 2026 - 2030
• Figure 4-1: Major Non-Invasive Routes For Insulin Delivery
• Figure 4-2: Controlled Drug Delivery Strategies In Cancer Therapy
• Figure 6-1: Global - Controlled Release Drug Clinical Pipeline By Phase (Number), 2025 Till 2030
• Figure 8-1: Namzaric - Price Per Unit & Supply (US$), August'2025
• Figure 8-2: Generic Donepezil/Memantine - Price Per Unit & Supply (US$), August'2025
• Figure 8-3: Namenda XR - Price Per Unit & Supply Of 7mg & 21mg Extended Release Capsules (US$), August'2025
• Figure 8-4: Namenda XR - Price Per Unit & Supply Of 14mg & 28mg Extended Release Capsules (US$), August'2025
• Figure 8-5: Namenda XR - Price Per Unit & Supply Of Extended Release Oral Kit (US$), August'2025
• Figure 8-6: Generic Memantine - Price Per Unit & Supply Of 7mg & 21mg Extended Release Capsules (US$), August'2025
• Figure 8-7: Generic Memantine - Price Per Unit & Supply Of 14mg Extended Release Capsules (US$), August'2025
• Figure 8-8: Generic Memantine - Price Per Unit & Supply Of 28mg Extended Release Capsules (US$), August'2025
• Figure 8-9: Razadyne ER - Price Per Unit & Supply (US$), August'2025
• Figure 8-10: Generic Galantamine - Price Per Unit & Supply (US$), August'2025
• Figure 9-1: Gocovri - Price Per Unit & Supply (US$), August'2025
• Figure 9-2: Global - Gocovri Annual Sales (US$ Million), 2021-2025
• Figure 9-3: Global - Gocovri Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 9-4: Global - Gocovri Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 9-5: Osmolex ER - Price Per Unit & Supply Of 322 mg Extended Release Tablet (US$), August'2025
• Figure 9-6: Osmolex ER - Price Per Unit & Supply Of 129 mg Extended Release Tablet (US$), August'2025
• Figure 9-7: Osmolex ER - Price Per Unit & Supply Of 193 mg Extended Release Tablet (US$), August'2025
• Figure 9-8: Osmolex ER - Price Per Unit & Supply Of 258 mg Extended Release Tablet (US$), August'2025
• Figure 9-9: Mirapex ER - Available Dosage Strengths (mg)
• Figure 9-10: Mirapex ER - Price Per Unit & Supply Of 0.375 mg & 0.75 mg Extended Release Tablets (US$), August'2025
• Figure 9-11: Mirapex ER - Price Per Unit & Supply Of 1.5 mg Extended Release Tablet (US$), August'2025
• Figure 9-12: Mirapex ER - Price Per Unit & Supply Of 2.25 mg, 3 mg, 3.75 mg & 4.5 mg Extended Release Tablets (US$), August'2025
• Figure 9-13: Generic Pramipexole - Price Per Unit & Supply Of 0.375 mg & 0.75 mg (US$), August'2025
• Figure 9-14: Generic Pramipexole - Price Per Unit & Supply Of 1.5 mg, 2.25 mg, 3 mg, & 4.5 mg (US$), August'2025
• Figure 9-15: Generic Pramipexole - Price Per Unit & Supply Of 3.75 mg (US$), August'2025
• Figure 10-1: Invega - Available Dosage Strengths (mg)
• Figure 10-2: Invega - Price Per Unit & Supply (US$), August'2025
• Figure 10-3: Invega Sustenna - Price Per Unit & Supply (US$), August'2025
• Figure 10-4: Invega Trinza - Price Per Unit & Supply (US$), August'2025
• Figure 10-5: Invega Hafyera - Price Per Unit & Supply (US$), August'2025
• Figure 10-6: Global - Invega Franchise Annual Sales (US$ Million), 2020-2025
• Figure 10-7: Global - Invega Franchise Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 10-8: Global - Invega Franchise Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 10-9: US - Invega Franchise Annual Sales (US$ Million), 2020-2025
• Figure 10-10: US - Invega Franchise Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 10-11: US - Invega Franchise Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 10-12: ROW - Invega Franchise Annual Sales (US$ Million), 2020-2025
• Figure 10-13: ROW - Invega Franchise Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 10-14: ROW - Invega Franchise Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 10-15: Seroquel XR - Available Dosage Strengths (mg)
• Figure 10-16: Seroquel XR - Price Per Unit & Supply (US$), August'2025
• Figure 10-17: Generic Quetiapine - Price Per Unit & Supply Of 60 Tablets (US$), August'2025
• Figure 10-18: Generic Quetiapine - Price Per Unit & Supply Of 100 Tablets (US$), August'2025
• Figure 10-19: Global - Seroquel XR Total Annual Sales (US$ Million), 2020-2021
• Figure 10-20: Abilify Maintena - Available Dosage Strengths (mg)
• Figure 10-21: Abilify Maintena - Price Per Supply of Vial & Prefilled Syringe (US$), August'2025
• Figure 10-22: Abilify Asimtufii - Price Per Unit & Supply (US$), August'2025
• Figure 10-23: Global - Abilify Franchise Annual Sales (US$ Million), 2020-2025
• Figure 10-24: Global - Abilify Franchise Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 10-25: Global - Abilify Franchise Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 10-26: Aristada - Available Dosage Strengths (mg)
• Figure 10-27: Aristada - Price Per Unit & Supply (US$), August'2025
• Figure 10-28: Aristada Initio - Price Per Unit & Supply (US$), August'2025
• Figure 10-29: Global - Aristada Franchise Annual Sales (US$ Million), 2020-2025
• Figure 10-30: Global - Aristada Franchise Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 10-31: Global - Aristada Franchise Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 10-32: Rykindo - Available Dosage Strengths (mg)
• Figure 10-33: Rykindo - Price Per Supply (US$), August'2025
• Figure 10-34: Generic Risperidone - Price Per Supply (US$), August'2025
• Figure 10-35: Risperdal Consta - Price Per Supply (US$), August'2025
• Figure 10-36: Global - Risperdal Consta Annual Sales (US$ Million), 2020-2021
• Figure 10-37: Uzedy - Price Per Unit & Supply (US$), August'2025
• Figure 11-1: Hysingla ER - Available Dosage Strengths (mg)
• Figure 11-2: Hysingla ER - Price Per Unit & Supply (US$), August'2025
• Figure 11-3: Generic Hydrocodone - Price Per Unit & Supply (US$), August'2025
• Figure 11-4: Nucynta ER - Available Dosage Strengths (mg)
• Figure 11-5: Nucynta ER - Price Per Unit & Supply (US$), August'2025
• Figure 11-6: Global - Nucynta ER Annual Sales (US$ Million), 2020-2025
• Figure 11-7: Global - Nucynta ER Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 11-8: Global - Nucynta ER Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 11-9: Kadian - Available Dosage Strengths (mg)
• Figure 11-10: Kadian - Price Per Unit & Supply Of Strength 10 mg/12 hr (US$), August'2025
• Figure 11-11: Kadian - Price Per Unit & Supply Of Strength 10 mg/12 to 24 hr & 10 mg/24 hr (US$), August'2025
• Figure 11-12: Kadian - Price Per Unit & Supply Of Strength 20 mg/12 hr (US$), August'2025
• Figure 11-13: Kadian - Price Per Unit & Supply Of Strength 20 mg/12 to 24 hr & 20 mg/24 hr (US$), August'2025
• Figure 11-14: Kadian - Price Per Unit & Supply Of Strength 30 mg/12 hr (US$), August'2025
• Figure 11-15: Kadian - Price Per Unit & Supply Of Strength 30 mg/12 to 24 hr & 30 mg/24 hr (US$), August'2025
• Figure 11-16: Kadian - Price Per Unit & Supply Of Strength 40 mg/12 to 24 hr & 40 mg/24 hr (US$), August'2025
• Figure 11-17: Kadian - Price Per Unit & Supply Of Strength 50 mg/12 hr (US$), August'2025
• Figure 11-18: Kadian - Price Per Unit & Supply Of Strength 50 mg/12 to 24 hr & 50 mg/24 hr (US$), August'2025
• Figure 11-19: Kadian - Price Per Unit & Supply Of Strength 60 mg/12 hr (US$), August'2025
• Figure 11-20: Kadian - Price Per Unit & Supply Of Strength 60 mg/12 to 24 hr (US$), August'2025
• Figure 11-21: Kadian - Price Per Unit & Supply Of Strength 60 mg/24 hr (US$), August'2025
• Figure 11-22: Kadian - Price Per Unit & Supply Of Strength 70 mg/12 to 24 hr (US$), August'2025
• Figure 11-23: Kadian - Price Per Unit & Supply Of Strength 80 mg/12 hr, 80 mg/12 to 24 hr & 80 mg/24 hr (US$), August'2025
• Figure 11-24: Kadian - Price Per Unit & Supply Of Strength 100 mg/12 hr, 100 mg/12 to 24 hr & 100 mg/24 hr (US$), August'2025
• Figure 11-25: Kadian - Price Per Unit & Supply Of Strength 130 mg/12 to 24 hr & 150 mg/12 to 24 hr (US$), August'2025
• Figure 11-26: Kadian - Price Per Unit & Supply Of Strength 200 mg/12 to 24 hr & 200 mg/24 hr (US$), August'2025
• Figure 11-27: Xtampza ER - Available Dosage Strengths (mg)
• Figure 11-28: Xtampza ER - Price Per Unit & Supply (US$), August'2025
• Figure 11-29: Global - Xtampza ER Annual Sales (US$ Million), 2020-2025
• Figure 11-30: Global - Xtampza ER Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 11-31: Global - Xtampza ER Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 11-32: MS Contin - Available Dosage Strengths (mg)
• Figure 11-33: MS Contin - Price Per Unit & Supply (US$), August'2025
• Figure 11-34: Embeda - Price Per Unit & Supply (US$), August'2025
• Figure 11-35: Zynrelef - Price Per Unit & Supply (US$), August'2025
• Figure 11-36: Global - Zynrelef Annual Sales (US$ Million), 2021-2025
• Figure 11-37: Global - Zynrelef Quarterly Sales (US$ Million), H1'2025
• Figure 11-38: Global - Zynrelef Quarterly Sales (US$ Million), 2024
• Figure 11-39: ConZip - Available Dosage Strengths (mg)
• Figure 11-40: ConZip - Price Per Unit & Supply (US$), August'2025
• Figure 11-41: Generic Hydromorphone - Available Dosage Strengths (mg)
• Figure 11-42: Generic Hydromorphone - Price Per Unit & Supply (US$), August'2025
• Figure 12-1: Ampyra - Price Per Unit & Supply (US$), August'2025
• Figure 12-2: Generic Dalfampridine - Price Per Unit & Supply (US$), August'2025
• Figure 12-3: ROW - Fampyra Annual Sales (US$ Million), 2020-2025
• Figure 12-4: ROW - Fampyra Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 12-5: Tecfidera - Available Dosage Strengths (mg)
• Figure 12-6: Tecfidera - Price Per Unit & Supply (US$), August'2025
• Figure 12-7: Generic Dimethyl Fumarate - Price Per Unit & Supply (US$), August'2025
• Figure 12-8: Global - Tecdifera Annual Sales (US$ Million), 2020-2025
• Figure 12-9: Global - Tecdifera Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 12-10: Global - Tecdifera Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 12-11: US - Tecdifera Annual Sales (US$ Million), 2020-2025
• Figure 12-12: US - Tecdifera Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 12-13: US - Tecdifera Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 12-14: ROW - Tecdifera Annual Sales (US$ Million), 2020-2025
• Figure 12-15: ROW - Tecdifera Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 12-16: ROW - Tecdifera Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 12-17: Vumerity - Price Per Unit & Supply (US$), August'2025
• Figure 12-18: Global - Vumerity Annual Sales (US$ Million), 2020-2025
• Figure 12-19: Global - Vumerity Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 12-20: Global - Vumerity Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 12-21: US - Vumerity Annual Sales (US$ Million), 2020-2025
• Figure 12-22: US - Vumerity Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 12-23: US - Vumerity Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 12-24: ROW - Vumerity Annual Sales (US$ Million), 2020-2025
• Figure 12-25: ROW - Vumerity Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 12-26: ROW - Vumerity Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 12-27: Rayos - Available Dosage Strengths (mg)
• Figure 12-28: Rayos - Price Per Unit & Supply (US$), August'2025
• Figure 12-29: US - Rayos Annual Sales (US$ Million), 2020-2023
• Figure 12-30: Global - Rayos Quarterly Sales (US$ Million), H1'2023
• Figure 12-31: Bafiertam - Price Per Unit & Supply (US$), August'2025
• Figure 13-1: Glumetza - Available Dosage Strengths (mg)
• Figure 13-2: Glumetza - Price Per Unit & Supply (US$), August'2025
• Figure 13-3: Generic Metformin - Price Per Unit & Supply Of 500mg (US$), August'2025
• Figure 13-4: Generic Metformin - Price Per Unit & Supply Of 1000mg (US$), August'2025
• Figure 13-5: Glucotrol XL - Available Dosage Strengths (mg)
• Figure 13-6: Glucotrol XL - Price Per Unit & Supply Of Strength 5 mg (US$), August'2025
• Figure 13-7: Glucotrol XL - Price Per Unit & Supply Of Strength 10 mg (US$), August'2025
• Figure 13-8: Generic Glipizide - Price Per Unit & Supply Of Strength 5 mg (US$), August'2025
• Figure 13-9: Generic Glipizide - Price Per Unit & Supply Of Strength 10 mg (US$), August'2025
• Figure 13-10: Glucophage XR - Available Dosage Strengths (mg)
• Figure 13-11: Glucophage XR - Price Per Unit & Supply Of Strength 10 mg (US$), August'2025
• Figure 13-12: Glucophage XR - Price Per Unit & Supply Of Strength 750 mg (US$), August'2025
• Figure 13-13: Trijardy XR - Price Per Unit & Supply Of Strengths 10 mg-5 mg-1000 mg & 25 mg-5 mg-1000 mg (US$), August'2025
• Figure 13-14: Trijardy XR - Price Per Unit & Supply Of Strengths 10 mg-5 mg-1000 mg & 25 mg-5 mg-1000 mg (US$), August'2025
• Figure 13-15: Synjardy XR - Price Per Unit & Supply Of 10 mg-1000 mg & 25 mg-1000 mg (US$), August'2025
• Figure 13-16: Synjardy XR - Price Per Unit & Supply Of 5 mg-1000 mg & 12.5 mg-1000 mg (US$), August'2025
• Figure 14-1: Procardia XL - Available Dosage Strengths (mg)
• Figure 14-2: Procardia XL - Price Per Unit & Supply Of 100 Tablets (US$), August'2025
• Figure 14-3: Procardia XL - Price Per Unit & Supply Of 300 Tablets (US$), August'2025
• Figure 14-4: Toprol XL - Available Dosage Strengths
• Figure 14-5: Toprol XL - Price Per Unit & Supply Of Strengths 25 mg, 50 mg & 200 mg (US$), August'2025
• Figure 14-6: Toprol XL - Price Per Unit & Supply Of Strengths 100 mg (US$), August'2025
• Figure 14-7: Global - Toprol XL Annual Sales (US$ Million), 2020-2024
• Figure 14-8: Global - Toprol XL Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 14-9: US - Toprol XL Annual Sales (US$ Million), 2020-2024
• Figure 14-10: EU - Toprol XL Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 14-11: EU - Toprol XL Annual Sales (US$ Million), 2020-2024
• Figure 14-12: EU - Toprol XL Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 14-13: ROW - Toprol XL Annual Sales (US$ Million), 2020-2024
• Figure 14-14: ROW - Toprol XL Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 14-15: Verelan PM - Available Dosage Strengths (mg)
• Figure 14-16: Verelan PM - Price Per Unit & Supply (US$), August'2025
• Figure 14-17: Generic Verapamil - Price Per Unit & Supply (US$), August'2025
• Figure 14-18: Cardizem LA - Available Dosage Strengths (mg)
• Figure 14-19: Cardizem LA - Price Per Unit & Supply Of 30 Tablets (US$), August'2025
• Figure 14-20: Cardizem LA - Price Per Unit & Supply Of 90 Tablets (US$), August'2025
• Figure 14-21: Calan SR - Available Dosage Strengths (mg)
• Figure 14-22: Calan SR - Price Per Unit & Supply Of 120 mg & 180 mg (US$), August'2025
• Figure 14-23: Calan SR - Price Per Unit & Supply Of 240 mg (US$), August'2025
• Figure 14-24: Altoprev - Available Dosage Strengths (mg)
• Figure 14-25: Altoprev - Price Per Unit & Supply (US$), August'2025
• Figure 14-26: Cardura XL - Available Dosage Strengths (mg)
• Figure 14-27: Cardura XL - Price Per Unit & Supply (US$), August'2025
• Figure 15-1: Apretude - Price Per Unit & Supply (US$), August'2025
• Figure 15-2: Cabenuva - Price Per Unit & Supply (US$), August'2025
• Figure 15-3: Rukobia - Price Per Unit & Supply (US$), August'2025
• Figure 16-1: Qelbree - Price Per Unit & Supply Of Strengths 100 mg & 150 mg (US$), August'2025
• Figure 16-2: Qelbree - Price Per Unit & Supply Of Strength 200 mg (US$), August'2025
• Figure 16-3: Global - Qelbree Annual Sales (US$ Million), 2021-2023
• Figure 16-4: Global - Qelbree Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 16-5: Global - Qelbree Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 16-6: Jornay PM - Available Dosage Strengths (mg)
• Figure 16-7: Jornay PM - Price Per Unit & Supply (US$), August'2025
• Figure 16-8: Global - Jornay PM Annual Sales (US$ Million), 2024-2025
• Figure 16-9: Global - Jornay PM Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 16-10: Global - Jornay PM Quarterly Sales (US$ Million), Q3-Q4'2024
• Figure 16-11: Cotempla XR-ODT - Available Dosage Strengths (mg)
• Figure 16-12: Cotempla XR-ODT - Price Per Unit & Supply (US$), August'2025
• Figure 16-13: Adzenys XR-ODT - Available Dosage Strengths (mg)
• Figure 16-14: Adzenys XR-ODT - Price Per Unit & Supply (US$), August'2025
• Figure 16-15: Global - Adzenys XR-ODT & Cotempla XR-ODT Annual Sales (US$ Million), 2021-2025
• Figure 16-16: Global - Adzenys XR-ODT & Cotempla XR-ODT Quarterly Sales (US$ Million), Q1'2025
• Figure 16-17: Global - Adzenys XR-ODT & Cotempla XR-ODT Quarterly Sales (US$ Million), Q1-Q4'2025
• Figure 16-18: Intuniv - Available Dosage Strengths (mg)
• Figure 16-19: Intuniv - Price Per Unit & Supply (US$), August'2025
• Figure 16-20: Global - Intuniv Annual Sales (US$ Million), 2020-2025
• Figure 16-21: Global - Intuniv Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 16-22: Focalin XR - Available Dosage Strengths (mg)
• Figure 16-23: Focalin XR - Price Per Unit & Supply (US$), August'2025
• Figure 17-1: Rinvoq - Available Dosage Strengths (mg)
• Figure 17-2: Rinvoq - Price Per Unit & Supply (US$), August'2025
• Figure 17-3: Global - Rinvoq Annual Sales (US$ Million), 2020-2025
• Figure 17-4: Global - Rinvoq Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 17-5: Global - Rinvoq Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 17-6: US - Rinvoq Annual Sales (US$ Million), 2020-2025
• Figure 17-7: US - Rinvoq Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 17-8: US - Rinvoq Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 17-9: ROW - Rinvoq Annual Sales (US$ Million), 2020-2025
• Figure 17-10: ROW - Rinvoq Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 17-11: ROW - Rinvoq Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 17-12: Ortikos - Available Dosage Strengths (mg)
• Figure 17-13: Ortikos - Price Per Unit & Supply (US$), August'2025
• Figure 17-14: Xeljanz XR - Available Dosage Strengths (mg)
• Figure 17-15: Xeljanz XR - Price Per Unit & Supply (US$), August'2025
• Figure 17-16: Global - Xeljanz XR Annual Sales (US$ Million), 2020-2025
• Figure 17-17: Global - Xeljanz XR Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 17-18: Global - Xeljanz XR Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 17-19: US - Xeljanz XR Annual Sales (US$ Million), 2020-2025
• Figure 17-20: US - Xeljanz XR Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 17-21: US - Xeljanz XR Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 17-22: ROW - Xeljanz XR Annual Sales (US$ Million), 2020-2025
• Figure 17-23: ROW - Xeljanz XR Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 17-24: ROW - Xeljanz XR Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 17-25: Mestinon Timespan - Price Per Unit & Supply (US$), August'2025
• Figure 17-26: Generic Pyridostigmine - Price Per Unit & Supply (US$), August'2025
• Figure 17-27: Symax Duotab - Price Per Unit & Supply (US$), August'2025
• Figure 18-1: Aemcolo - Price Per Unit & Supply (US$), August'2025
• Figure 18-2: Talicia - Price Per Unit & Supply (US$), August'2025
• Figure 19-1: Sublocade - Price Per Unit & Supply (US$), August'2025
• Figure 19-2: Global - Sublocade Annual Sales (US$ Million), 2020-2025
• Figure 19-3: Global - Sublocade Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 19-4: Global - Sublocade Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 19-5: Sublocade - Price Per Unit & Supply Of Strength 50 mg/mL (US$), August'2025
• Figure 19-6: Sublocade - Price Per Unit & Supply Of Strength 355.6 mg/mL (US$), August'2025
• Figure 20-1: Astagraf XL - Available Dosage Strengths (mg)
• Figure 20-2: Astagraf XL - Price per Unit & Supply (US$), August'2025
• Figure 20-3: Envarsus XR - Available Dosage Strengths (mg)
• Figure 20-4: Envarsus XR - Price per Unit & Supply Of 30 Tablets (US$), August'2025
• Figure 20-5: Envarsus XR - Price per Unit & Supply Of 100 Tablets (US$), August'2025
• Figure 21-1: Trokendi XR - Available Dosage Strengths (mg)
• Figure 21-2: Trokendi XR - Price per Unit & Supply (US$), August'2025
• Figure 21-3: Global - Trokendi XR Annual Sales (US$ Million), 2020-2025
• Figure 21-4: Global - Trokendi XR Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 21-5: Global - Trokendi XR Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 21-6: Global - Oxtellar XR Annual Sales (US$ Million), 2020-2025
• Figure 21-7: Global - Oxtellar XR Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 21-8: Global - Oxtellar XR Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 21-9: Keppra XR - Available Dosage Strengths (mg)
• Figure 21-10: Keppra XR - Price per Unit & Supply (US$), August'2025
• Figure 21-11: Generic levetiracetam - Price per Unit & Supply Of 500 mg (US$), August'2025
• Figure 21-12: Keppra XR - Price per Unit & Supply (US$), August'2025
• Figure 21-13: Global - Oxtellar XR Annual Sales (US$ Million), 2020-2025
• Figure 21-14: Roweepra XR - Available Dosage Strengths (mg)
• Figure 21-15: Roweepra XR - Price per Unit & Supply (US$), August'2025
• Figure 21-16: Depakote - Available Dosage Strengths (mg)
• Figure 21-17: Depakote - Price per Unit & Supply (US$), August'2025
• Figure 21-18: Depakote ER - Available Dosage Strengths (mg)
• Figure 21-19: Depakote ER - Price per Unit & Supply (US$), August'2025
• Figure 21-20: Depakote Sprinkles - Price per Unit & Supply (US$), August'2025
• Figure 22-1: Effexor XR - Available Dosage Strengths (mg)
• Figure 22-2: Effexor XR - Price per Unit & Supply Of 30 Capsules (US$), August'2025
• Figure 22-3: Effexor XR - Price per Unit & Supply Of 90 Capsules (US$), August'2025
• Figure 22-4: Generic Venlafaxine - Price per Unit & Supply Of 37.5 mg (US$), August'2025
• Figure 22-5: Generic Venlafaxine - Price per Unit & Supply Of 37.5 mg (US$), August'2025
• Figure 22-6: Generic Venlafaxine - Price per Unit & Supply Of 37.5 mg (US$), August'2025
• Figure 22-7: Global - Effexor XR Annual Sales (US$ Million), 201-2025
• Figure 22-8: Global - Effexor XR Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 22-9: Global - Effexor XR Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 22-10: Xanax XR - Available Dosage Strengths (mg)
• Figure 22-11: Xanax XR - Price per Unit & Supply (US$), August'2025
• Figure 22-12: Generic Alprazolam - Price per Unit & Supply (US$), August'2025
• Figure 22-13: Ambien CR - Available Dosage Strengths (mg)
• Figure 22-14: Ambien CR - Price per Unit & Supply (US$), August'2025
• Figure 22-15: Generic Zolpidem - Price per Unit & Supply Of 6.25 mg (US$), August'2025
• Figure 22-16: Generic Zolpidem - Price per Unit & Supply Of 12.5 mg (US$), August'2025
• Figure 23-1: Klor-Con 8 - Price per Unit & Supply (US$), August'2025
• Figure 23-2: Generic Potassium Chloride - Price per Unit & Supply Of 8 mEq (US$), August'2025
• Figure 23-3: Klor-Con 10 - Price per Unit & Supply (US$), August'2025
• Figure 23-4: Klor-Con M10 - Price per Unit & Supply (US$), August'2025
• Figure 23-5: Klor-Con M15 - Price per Unit & Supply (US$), August'2025
• Figure 23-6: Generic Potassium Chloride - Price per Unit & Supply Of 15 mEq (US$), August'2025
• Figure 23-7: Klor-Con M20 - Price per Unit & Supply (US$), August'2025
• Figure 24-1: Controlled Drug Delivery System Market - Key Drivers
• Figure 24-2: Controlled Drug Delivery System Market - Major Challenges

List of Tables

• Table 1-1: Conventional vs. Novel Drug Delivery
• Table 1-2: Sustained vs. Controlled Release
• Table 5-1: Controlled Release Drugs - Recent US FDA Approvals